Drugs Made In America Acquisition Corp. (DMAAR) Accumulated Expenses (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Accumulated Expenses for 3 consecutive years, with $10500.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses fell 92.88% year-over-year to $10500.0; the trailing twelve-month figure through Jun 2026 stood at $10500.0 (down 92.88% YoY), and the FY2024 full-year result was $77280.0, changed N/A from the prior year.
• Accumulated Expenses retreated to $10500.0 in Q2 2026 per DMAAR's latest filing, from $302623.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $302623.0 in Q3 2025 and bottomed at $10500.0 in Q2 2026.
• Historically, Accumulated Expenses has averaged $134067.8 across 3 years, with a median of $132483.0 in 2025.
• The widest YoY moves for Accumulated Expenses: up 92.88% in 2026, down 92.88% in 2026.
• Over 3 years, Accumulated Expenses stood at $77280.0 in 2024, then jumped by 291.59% to $302623.0 in 2025, then plunged by 96.53% to $10500.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $10500.0, $302623.0, and $147453.0 for Q2 2026, Q3 2025, and Q2 2025 respectively.